A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Tovecimig (Primary) ; Paclitaxel
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms COMPANION-002
- Sponsors Compass Therapeutics
Most Recent Events
- 29 Apr 2025 Results presented in the Elpiscience Biopharmaceuticals Media Release.
- 21 Apr 2025 According to a Compass Therapeutics media release, company expect to report results of the secondary endpoints in the Phase 2/3 Study, including progression-free survival (PFS) and overall survival (OS), in the fourth quarter of this year.
- 01 Apr 2025 According to a Compass Therapeutics media release, company will host a webcast today, Tuesday, April 1, 2025 at 8:00a.m. ET to provide a review of the tovecimig top-line COMPANION-002 data.